AU Patent

AU2009330686B2 — Compounds for the treatment of cancer

Assigned to University of Tennessee Research Foundation · Expires 2014-07-03 · 12y expired

What this patent protects

Compounds according to formula (I) are disclosed, (I), where Q is S, N, or O; X is optional, and can be O=, S=, =N-NH

USPTO Abstract

Compounds according to formula (I) are disclosed, (I), where Q is S, N, or O; X is optional, and can be O=, S=, =N-NH

Drugs covered by this patent

dabrafenib-mesylate (DABRAFENIB MESYLATE)

Patent Metadata

Patent number: AU2009330686B2
Jurisdiction: AU
Classification: —
Expires: 2014-07-03
Drug substance claim: No
Drug product claim: No
Assignee: University of Tennessee Research Foundation
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.